BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Veru Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Veru Inc.'s drugs run\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07446998-264@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:enobosarm: Phase 2 readout est. (NCT07446998)
DESCRIPTION:enobosarm\, phase 2\, Obesity.\nStudy: Proof-of-Concept Study E
 valuating Total Body Weight\, Physical Function & Safety of Enobosarm in P
 atients Treated With GLP-1 Receptor Agonist\, for Weight Loss\nEstimated p
 rimary completion: October 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/enobosarm#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07446998
URL:https://assetmemo.bio/drug/enobosarm#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
